{"id":"NCT01352845","sponsor":"Pfizer","briefTitle":"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.","officialTitle":"A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2011-05-12","resultsPosted":"2016-02-23","lastUpdate":"2016-02-23"},"enrollment":3301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"rLP2086","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"rLP2086","type":"EXPERIMENTAL"},{"label":"Control","type":"PLACEBO_COMPARATOR"}],"summary":"This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young adults. The study will also look at the safety of the new vaccine as well as how it is tolerated.","primaryOutcome":{"measure":"Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1","timeFrame":"One month after third bivalent rLP2086 vaccination","effectByArm":[{"arm":"Group 1 rLP2086","deltaMin":84.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":58,"countries":["United States","Canada","Denmark","Finland","Poland","Spain"]},"refs":{"pmids":["35164991","32700260","32681472","29236639"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971016&StudyName=A%20Trial%20to%20Assess%20the%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20Bivalent%20rLP2086%20Vaccine%20When%20Given%20to%20Healthy%20Young%20Adults%20Aged%20greater%20than%3D18%20to%20less%20than26%20Years"]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":2471},"commonTop":["Pain at injection site - Any (reactogenicity event)","Fatigue -Any (reactogenicity event)","Headache - Any (reactogenicity event)","Muscle pain -Any (reactogenicity event)","Joint pain -Any (reactogenicity event)"]}}